Disparities in PET Imaging for Prostate Cancer at a Tertiary Academic Medical Center

J Nucl Med. 2021 May 10;62(5):695-699. doi: 10.2967/jnumed.120.251751. Epub 2020 Sep 25.


The purpose of this study was to evaluate differences between patients receiving 18F-fluciclovine and 68Ga-prostate-specific membrane antigen (68Ga-PSMA-11) for biochemically recurrent prostate cancer at a tertiary medical center. Methods: All 18F-fluciclovine and 68Ga-PSMA-11 PET studies performed at the University of California San Francisco from October 2015 to January 2020 were reviewed. Age, race/ethnicity, primary language, body mass index, insurance type, and home address were obtained through the electronic medical record. A logistic regression model was used to evaluate the predictor variables. Results: In total, 1,502 patients received 68Ga-PSMA-11 and 254 patients received 18F-fluciclovine. Black patients had increased odds of receiving imaging with 18F-fluciclovine versus 68Ga-PSMA-11 compared with non-Hispanic White patients (odds ratio, 3.88; 95% CI, 1.90-7.91). There were no other statistically significant differences. Conclusion: In patients receiving molecular imaging for prostate cancer at a single U.S. tertiary medical center, access to 68Ga-PSMA-11 for Black patients was limited, compared with non-Hispanic White patients, by a factor of nearly 4.

Keywords: 18F-fluciclovine; 68Ga-PSMA-11; PET; health disparities; prostate cancer.

MeSH terms

  • Academic Medical Centers / statistics & numerical data*
  • Humans
  • Male
  • Positron-Emission Tomography / statistics & numerical data*
  • Prostatic Neoplasms / diagnostic imaging*
  • Tertiary Care Centers / statistics & numerical data*